Post clinical trial, the safety and efficacy of a drug is the only way the population can determine the long-term acceptance of new and existing drugs. Patients in today’s market are bombarded with marketing efforts with little thought to large population dosing studies. In recent reports, there is anecdotal evidence that the market confirms the value of information collected from registries coupled with rigorous analysis followed by clear reporting. The analysis can be initiated during or after the phase I and phase II completions. M/A/R/C Rx will monitor Adverse Event Reactions (AERs or AEs).
To request more information, click here.